Skip to content

Evidence Explorer · EV-014

DHTs in drug development

FDA opened a 2026 funding opportunity to explore digital health technologies such as actigraphy, photography, and contactless sensors in drug development.

E591/100 confidenceFederal funding opportunity

What this evidence supports

FDA is funding work on digital health technologies for data collection and measurement in drug development.

What it does not establish

A funding opportunity is not evidence that any DHT measure is validated or accepted as a regulatory endpoint.

Record details

Source authority: FDA
Evidence level: E5
Directness: 5/5
Recency: 5/5
Decision relevance: 4/5
Date: 2026-07-23

Primary source

https://www.fda.gov/science-research/science-and-research-special-topics/digital-health-technologies-dhts-drug-development

Related intelligence

FDA opens funding opportunity to study digital health technologies in drug development